Is Amicus Therapeutics Inc (FOLD) overvalued? · rev $528.3M
Amicus Therapeutics Inc (FOLD) is a biotechnology company listed on US.
This page asks whether Amicus Therapeutics Inc (FOLD) looks expensive on cached numbers — not a short thesis.
Latest reported FOLD revenue for 2024-12-31 was $528.3M. Net income was -$56.1M. Revenue was up 32.3% from 2023-12-31 to 2024-12-31. FOLD currently screens at market cap $1.80B.
FOLD currently screens at market cap $1.80B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next FOLD 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the FOLD stock page for the full model, not this heading.
Not investment advice.